General | Ionis Pharmaceuticals, Inc.

Skip to main navigation

Investors
Newsroom
Medical Professionals
Careers
- Intern Program
- Postdoctoral Program
Contact Us

Main navigation

About Us
Areas of Focus
Science & Innovation
Medicines
Patients & Advocacy

Media Center

Investor Relations

Overview
Investor News
Events
Stock Information
Financials
- SEC Filings
- Annual Reports
Governance
- Governance Documents
- Committee Composition
Investor Resources
Investor Email Alerts

Investor contact

Media contact

code

General

Ionis to host 2026 virtual Annual Meeting of Stockholders

Read more about Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis to present at upcoming investor conferences

Read more about Ionis to present at upcoming investor conferences

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Read more about Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Read more about Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Ionis to hold first quarter 2026 financial results webcast

Read more about Ionis to hold first quarter 2026 financial results webcast

Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

Read more about Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review

Ionis announces changes to Board of Directors

Read more about Ionis announces changes to Board of Directors

Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

Read more about Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting

Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

Read more about Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)

Ionis to present at upcoming investor conferences

Read more about Ionis to present at upcoming investor conferences

Pagination

Page 1
Next page

Subscribe to General

Footer Navigation

Legal and Compliance:
Information For:
Explore:
Stay Connected:
- Contact Us
- LinkedIn
- X
- Instagram
- Facebook
- Community Guidelines

©1989 – 2026 Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
Akcea Therapeutics® is a wholly owned subsidiary of Ionis Pharmaceuticals, Inc.